
Day One Biopharmaceuticals, Inc.
NASDAQ:DAWN
8.79 (USD) • At close March 12, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|---|---|
Revenue
| 131.161 | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue
| 5.279 | 0.383 | 0.531 | 0.199 | 0.155 | 0 |
Gross Profit
| 125.882 | -0.383 | -0.531 | -0.199 | -0.155 | 0 |
Gross Profit Ratio
| 0.96 | 0 | 0 | 0 | 0 | 0 |
Reseach & Development Expenses
| 227.702 | 130.521 | 85.618 | 43.584 | 9.1 | 13.899 |
General & Administrative Expenses
| 0 | 75.543 | 61.291 | 29.159 | 4.682 | 1.006 |
Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 115.45 | 75.543 | 61.291 | 29.159 | 4.682 | 1.006 |
Other Expenses
| 0 | 0 | -0.018 | -0.015 | -0.031 | -0.002 |
Operating Expenses
| 343.152 | 206.064 | 146.909 | 72.743 | 13.782 | 14.905 |
Operating Income
| -217.27 | -206.064 | -146.909 | -72.743 | -13.782 | -14.905 |
Operating Income Ratio
| -1.657 | 0 | 0 | 0 | 0 | 0 |
Total Other Income Expenses Net
| 128.918 | 17.147 | 4.728 | -0.011 | -30.061 | -2.079 |
Income Before Tax
| -88.352 | -188.917 | -142.181 | -72.754 | -43.843 | -16.984 |
Income Before Tax Ratio
| -0.674 | 0 | 0 | 0 | 0 | 0 |
Income Tax Expense
| -7.144 | 0 | -10.005 | -2.312 | -3.337 | -2.273 |
Net Income
| -95.496 | -188.917 | -132.176 | -70.442 | -40.506 | -14.711 |
Net Income Ratio
| -0.728 | 0 | 0 | 0 | 0 | 0 |
EPS
| -1.02 | -2.37 | -2.02 | -1.14 | -0.65 | -0.24 |
EPS Diluted
| -1.02 | -2.37 | -2.02 | -1.14 | -0.65 | -0.24 |
EBITDA
| -217.27 | -206.064 | -141.65 | -72.555 | -43.658 | -0.002 |
EBITDA Ratio
| -1.657 | 0 | 0 | 0 | 0 | 0 |